|Bid||109.08 x 0|
|Ask||109.20 x 0|
|Day's Range||108.33 - 112.80|
|52 Week Range||95.88 - 180.00|
|Beta (5Y Monthly)||0.57|
|PE Ratio (TTM)||17.69|
|Earnings Date||Aug 25, 2021 - Aug 30, 2021|
|Forward Dividend & Yield||0.35 (0.29%)|
|Ex-Dividend Date||Jul 07, 2021|
|1y Target Est||100.77|
BGI is aware of reports in Reuters regarding the company's non-invasive prenatal test (NIPT test) - NIFTY (Non-Invasive Fetal TrisomY).
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, and BGI Genomics Co., Ltd., (300676.SZ), one of the world's leading genomics companies, today announced the launch of the BGI/Natera Signatera Assay which is now available to biopharmaceutical customers and clinicians across China.
The Chinese government has made an investment in BGI Genomics Co, a listed Chinese company that has supplied millions of COVID-19 tests globally as the gene firm seeks to fund exponential growth driven by the pandemic. BGI Group, which runs a massive gene databank in China and has DNA sequencing contracts with health firms and universities worldwide, has in the past responded to claims from U.S. security agencies that it is closely linked to the Chinese government by saying it has no Chinese government capital. BGI Genomics, the company's subsidiary listed on the Shenzhen stock exchange, raised the equivalent of just over $300 million in a private placement to investors including China's biggest state investment vehicle, the State Development and Investment Corp (SDIC), filings to the exchange on Feb. 1 show.